My categorisation of Witan Investment Trust (LSE: WTAN), the £2bn global investment fund, as a “lame duck” at the start of the year brought an immediate response from its lead manager, Andrew Bell. I had written that its investment record, a 4% return over one year and 15% over five, was dismal, it had been too slow in reducing a heavy UK exposure and that the “fund-of-funds” investment model had proved inflexible.
Bell admitted to being “wrongfooted” by the pandemic but explained that they had taken early action, allocating 14% of the trust to two new “quality/growth” managers. He expressed confidence that the reduced but still large UK exposure was starting to work in the trust’s favour and was keen to avoid being whipsawed by making radical changes. The trust had bought back 7% of its shares and he had twice added to his personal holding. Performance in absolute terms and relative to benchmark had been positive for seven consecutive months.
Eclipsing the World index
Since then, performance has been strong so that the 12-month return is now 36%, more than 11% ahead of the MSCI All Countries World index and among the best in the sector. Comparing Witan to Alliance Trust, Iain Scouller of brokers Stifel writes: “While Alliance is still ahead on two-year performance, Witan’s performance has rebounded strongly.” Alliance is managed by the investment consultancy arm of Willis Towers Watson using a similar “multi-manager” approach: it subcontracts investment management to carefully chosen investment managers around the world.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Witan uses Willis Towers Watson’s database to screen for promising managers but no longer takes advice from them. This looks sensible. The departure from Willis Towers Watson last year of David Shapiro, Alliance’s day-to-day manager, has left Alliance’s performance, a 30% gain in the last year, lagging Witan’s. Without Shapiro, it is hard to believe that Willis Towers Watson’s institutional culture is suited to managing a trust with shareholders looking for a bit of flair.
Growth at a reasonable price
By contrast, the commitment of Bell and his co-manager, James Hart, is indisputable. Their style “is centred on growth at a reasonable price” but the six core managers, accounting for 75% of the portfolio, include the value-orientated Veritas. Five of these managers are global and only one, Artemis, is UK-focused. 23% of the portfolio is in specialist funds, including 11% directly invested in trusts in the areas of private equity (Electra, Apax Global and Princess), property (Schroder Real Estate) and biotech (Syncona). Bell points to the 66% return on Electra shares in the second quarter as evidence of how this adds value.
About 7% is invested in an emerging-markets fund and 4% in the GMO Climate Change Fund. Bell accepts that they were late in buying into this theme but is adding on setbacks. Meanwhile, 2% is in an S&P 500 exchange-traded fund (ETF) to raise US exposure to 38% of the portfolio, excluding the investment trusts. And 21% is in the UK, showing that this is through the stockpicking of the underlying managers rather than a top-down allocation. Witan’s managers clearly deem UK equities undervalued.
Holdings are reviewed quarterly: “There is a danger in getting too much information but it’s useful to keep an eye on what the managers are doing,” says Hart. Borrowings finance nearly 10% of the portfolio, reflecting an optimistic view of long-term potential. The shares trade at an 8% discount to net asset value (NAV) and yield 2.3%. This sounds underwhelming but the dividend has been increased every year for 46 years.
Witan’s revival looks set to continue. It should deliver steady, benchmark-beating low-risk performance with rising income. Most importantly, it has shown an ability to resolve performance issues promptly.
Max has an Economics degree from the University of Cambridge and is a chartered accountant. He worked at Investec Asset Management for 12 years, managing multi-asset funds investing in internally and externally managed funds, including investment trusts. This included a fund of investment trusts which grew to £120m+. Max has managed ten investment trusts (winning many awards) and sat on the boards of three trusts – two directorships are still active.
After 39 years in financial services, including 30 as a professional fund manager, Max took semi-retirement in 2017. Max has been a MoneyWeek columnist since 2016 writing about investment funds and more generally on markets online, plus occasional opinion pieces. He also writes for the Investment Trust Handbook each year and has contributed to The Daily Telegraph and other publications. See here for details of current investments held by Max.
From oil to copper: how to trade wisely when capitalising on mega trends
By MoneyWeek Published
Retailer price inflation falls to near-2 year low, new figures show
A fall in supermarket inflation led the way, with fresh food price hikes dropping significantly since January.
By Henry Sandercock Published
M&S is back in fashion: but how long can this success last?
M&S has exceeded expectations in the past few years, but can it keep up the momentum?
By Rupert Hargreaves Published
The end of China’s boom
Like the US, China too got fat on fake money. Now, China's doom is not far away.
By Bill Bonner Published
Magic mushrooms — an investment boom or doom?
Investing in these promising medical developments might see you embark on the trip of a lifetime.
By Bruce Packard Published
What pension providers don't tell you about your retirement money
Check the small print from your pension provider or risk losing thousands.
By Merryn Somerset Webb Published
Should you invest in sector funds?
Sector funds can be a useful way to fine-tune a portfolio or track a theme, but check what the index holds.
By Cris Sholto Heaton Published
Three high-quality global companies for growth
James Harries, a senior fund manager at STS Global Income & Growth Trust highlights three favourites.
By James Harries Published
Four high-quality stocks set for decades of dividend and earnings growth
Charles Luke, an investment manager for Murray Income Trust, highlights four favourite high-quality stocks.
By Charles Luke Published
Humana sees healthy growth in US healthcare
Humana is a major player in the American market and the stock’s valuation looks reasonable.
By Stephen Connolly Published